0001193125-26-221565
SEC filingHeartBeam reported a narrower operating loss and improved cash burn in Q1 FY2026 versus prior year, reflecting continued execution on its commercial launch; however, the company remains pre-revenue and has explicitly stated its existing liquidity is insufficient to fund operations for the next twelve months.
The Company confirmed no unregistered sales of equity securities occurred during Q1 FY2026. This aligns with Item 2 disclosures and underscores reliance on registered capital markets — notably the April 16, 2026 underwriting agreement referenced in the exhibits — to meet near-term funding needs. Absent private placements or debt alternatives, this constraint heightens the importance of timely execution against registered financing milestones.
Atelier Health’s expansion into Southern California represents HeartBeam’s first documented commercial footprint. Per the filing’s Full Filing Text, this initiative establishes a foundation across targeted launch markets and enables broader national expansion. Unlike prior development-phase activity, this step introduces real-world clinical network engagement — a prerequisite for generating usage data, refining commercial assumptions, and de-risking future capital raises. It does not signal revenue generation, but rather the transition from product development to controlled market introduction.
Management explicitly states that, based on current business plan assumptions and expected cash burn rate, existing liquidity is insufficient to fund operations for the next twelve months following issuance of these financial statements. This disclosure is repeated verbatim in two sections of the filing and reflects an unchanged risk posture from prior periods. The $3.6M net cash used in operations — while improved from $4.5M in Q1 FY2025 — continues to outpace inflows, and the $246K in capital expenditures confirms initiation of hardware-related deployment activity, which may further pressure near-term liquidity absent new funding.